top of page
  • Ann-Christine Jungmar

Tridentify announces an LOI purchase commitment for clinical trials with Parkinson’s diseases patients

Date: 2024-04-09


Tridentify are delighted to announce that Intrance Medical Systems Inc. now have signed a LOI purchase commitment of $ 300 000. Our Tridentify safeguarding solution will be used for the “logistic journey” of the drug component for clinical trials in at least Europe and the US for patients with Parkinson diseases in advanced stage. The clinical development program for US registration has recently been initiated, with a larger more extensive study planned for late 2024. 


- Intrance Medical Systems is focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinson’s disease. The product, Lecigon, is successfully marketed and available across Europe (by Britannia Pharmaceuticals). Intrance Medical plans to bring this innovative system to the US, Canada, Japan, Taiwan and LATAM. The US clinical development program includes key studies where accurate data to the FDA is paramount. Since Lecigon requires an unbroken cold supply chain and whose properties can change if improperly handled, we have found that Tridentify has a unique solution with monitoring and continuous calculation of remaining shelf life. We’re excited about our collaboration and anticipate extending our partnership in the future, says Patrick Shea, CEO at Intrance Medical Systems Inc.


Tridentify is excited about the next steps with Intrance Medical Inc. Together with Intrance we want to ensure high quality standards in their important development of a new Parkinson treatment. We are proud to be able to safeguard the shipments for the clinical trials in Europe and in the US, as well as to support the important safety for patients with severe diseases, says Ann-Christine Jungmar, CEO at Tridentify.


About Tridentify AB

Tridentify is a Swedish Software-as-a-Service MedTech company that helps customers control the entire supply chain and cold chain logistics for costly sensitive drugs, vaccines, blood, organs and other temperature-sensitive goods. The company has a unique and patented SaaS/IoMT system that monitors in real time the status of the product and continuously calculates its remaining shelf-life and that it safely fulfils its purpose. With the Safeguarding solution, you always have a close eye on how your temperature sensitive products are doing during the journey. Unlike other solutions, Tracer System® is programmed to understand and sense exactly how different types of medicines, vaccines, blood, plasma and organs are affected during a transport, throughout the life cycle of the products.


With our medical technology - not just a logistics tool - sensitive goods can be put into use immediately after delivery without a formal QA. A revolution in industry to save time, money and most importantly - ensure security and functionality for the end user!  Our technology makes it safer and easier to comply with current and future legislation and medical requirements. In the end, this means safe products, safe patients and minimal wastage.


Tridentify has a SaaS solution using a unique IoT Tracer that is a MDD MedTech Device Class IIa*.

*MDD Certificate extended to end of 2028 due to Article 120 of MDR


For more information, visit


About Intrance Medical Systems Inc

Intrance Medical Systems, Inc., is a private, U.S.-based biopharmaceutical company focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinson’s disease in the U.S., Canada, South America, Japan and Taiwan. Intrance’s lead product, known as Lecigon® in the European market, is a fixed-dose combination treatment of levodopa, carbidopa and entacapone for enteral infusion in advanced Parkinson’s disease patients. The company has received FDA clearance for its IND application and is advancing its clinical development program for this targeted indication.


For more information, visit 


For further information, kindly contact:

Ann-Christine Jungmar, CEO Tridentify

+46 708 71 46 76



bottom of page